Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEOPARD-Neo trial of lenvatinib plus hepatic arterial cisplatin before resection in borderline resectable hepatocellular carcinoma
jRCTs031230128Phase 2Active, not recruiting
- Sponsor
- Guardant Health
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and cisplatin in hepatocellular carcinoma (HCC), sponsored by Guardant Health. Primary endpoint: Resection rate. Started Oct 2023; status: active, not recruiting.
02
Drugs
lenvatinibcisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031230128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230128.